Shares of Hikma Pharmaceuticals PLC HIK rallied 1.05% to £20.14 Thursday, on what proved to be an all-around favorable ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 ...

Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,922.34 ($24.05) ...

The fight against type 2 diabetes just reached a groundbreaking milestone. Last week, the U.S. Food and Drug Administration ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

In this article, we are going to take a look at where Hikma Pharmaceuticals PLC (LON:HIK.L) stands against the other U.K.

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.35% to £19.82 Friday, on what proved to be an all-around favorable ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals) ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

The global dyspnea treatment market, valued at USD 6.31 billion in 2023, is poised for remarkable growth, with projections ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 ...